"Pharmacoepidemiology" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The science concerned with the benefit and risk of drugs used in populations and the analysis of the outcomes of drug therapies. Pharmacoepidemiologic data come from both clinical trials and epidemiological studies with emphasis on methods for the detection and evaluation of drug-related adverse effects, assessment of risk vs benefit ratios in drug therapy, patterns of drug utilization, the cost-effectiveness of specific drugs, methodology of postmarketing surveillance, and the relation between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines. (Pharmacoepidemiol Drug Saf 1992;1(1); J Pharmacoepidemiol 1990;1(1))
Descriptor ID |
D017891
|
MeSH Number(s) |
H01.158.703.045 H02.403.720.500.650 H02.628.413
|
Concept/Terms |
Pharmacoepidemiology- Pharmacoepidemiology
- Pharmaceutical Epidemiology
- Epidemiologies, Pharmaceutical
- Pharmaceutical Epidemiologies
- Epidemiology, Pharmaceutical
|
Below are MeSH descriptors whose meaning is more general than "Pharmacoepidemiology".
Below are MeSH descriptors whose meaning is more specific than "Pharmacoepidemiology".
This graph shows the total number of publications written about "Pharmacoepidemiology" by people in this website by year, and whether "Pharmacoepidemiology" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2008 | 1 | 0 | 1 |
2012 | 1 | 1 | 2 |
2013 | 2 | 1 | 3 |
2014 | 0 | 1 | 1 |
2015 | 0 | 3 | 3 |
2019 | 1 | 2 | 3 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacoepidemiology" by people in Profiles.
-
The?application of lag times in cancer pharmacoepidemiology: a narrative review. Ann Epidemiol. 2023 08; 84:25-32.
-
High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reporting. Pharmacoepidemiol Drug Saf. 2023 Feb; 32(2):93-106.
-
Population-Based Signals of Antidepressant Drug Interactions Associated With Unintentional Traumatic Injury. Clin Pharmacol Ther. 2021 08; 110(2):409-423.
-
Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. Biomed Pharmacother. 2020 Oct; 130:110531.
-
Blood pressure lowering medication initiation and fracture risk: a SWAN pharmacoepidemiology study. Arch Osteoporos. 2019 06 28; 14(1):73.
-
Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding. Ann Epidemiol. 2019 07; 35:42-47.e1.
-
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations. Epidemiology. 2019 03; 30(2):230-233.
-
Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes Control. 2016 May; 27(5):709-20.
-
Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev. 2015 Nov 05; 4:147.
-
Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases. Pharmacoepidemiol Drug Saf. 2015 Jul; 24(7):684-92.